Predict your next investment

Venture Capital
samsaracap.com

See what CB Insights has to offer

Investments

70

Portfolio Exits

17

Funds

2

About Samsara BioCapital

Samsara BioCapital is a Palo Alto-based venture capital firm.

Samsara BioCapital Headquarter Location

628 Middlefield Road

Palo Alto, California, 94301,

United States

650-285-4270

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Samsara BioCapital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Samsara BioCapital in 2 CB Insights research briefs, most recently on Sep 9, 2019.

Latest Samsara BioCapital News

San Diego biotech veterans launch novel therapeutics firm targeting cancer, other diseases

Oct 16, 2021

San Diego biotech veterans launch novel therapeutics firm targeting cancer, other diseases (The San Diego Union-Tribune) Tentarix comes out of stealth mode, raises $50 million in venture funding led by Versant Ventures, Samsara BioCapital Print San Diego’s Tentarix Biotherapeutics emerged from stealth mode this week with $50 million in the bank to pursue precision therapies against cancer and other diseases. Founded by San Diego and Vancouver, B.C., biotech veterans, Tentarix pulled its Series A funding from Versant Ventures and Samsara BioCapital. Versant recently invested in another early stage San Diego biotech company, 858 Therapeutics, which raised $60 million earlier this month. Tentarix’s technology is complicated. But the company has come up with a proprietary, high-volume discovery platform to uncover antibody-like molecules that trigger an immune response against diseased cells while leaving healthy cells alone. Advertisement “It is really more about understanding the precise way that we can activate that subset of T-cells without activating other cells that either could have a negative effect or could diminish (the effectiveness) of cancer-fighting therapeutics that the patient is on,” said Paul Grayson, co-founder and chief executive of Tentarix. The field is knowns as multifunctional biotherapeutics. To this point, it has been someone limited — in part because of difficulties uncovering antibody-like molecules at scale that can trigger an immune response in diseased cells without side effects. Tentarix aims to solve this problem through its platform — which could enable delivery of higher doses of therapeutics to fight cancer cells. “The ability to screen millions of multifunctional molecules for activity and conditionality is a breakthrough,” said Jerel Davis, a managing director at Versant. “We believe the team and technology assembled at Tentarix will enable a pipeline of first-in-class biologics with unique function.” It is still early days. Grayson hopes to have the first therapeutic ready for clinical trials in mid-2023. For now, the company believes its technology is most applicable to tumors associated with breast, lung and pancreatic cancer. Tentarix’s founders have roots in the San Diego biotech scene. Grayson came from Fate Therapeutics, Aurora Biosciences, Senomyx and Bird Rock Bio. The company’s chief science officer, Stephen Demarest, worked at Scripps and then joined IDEC Pharmaceuticals — later Biogen-IDEC. Demarest ended up at Eli Lilly, where he was head of the protein engineering and computational biotherapeutics departments. Tentarix has 17 employees in San Diego and about 15 in Vancouver, which is the company’s co-headquarters. The Vancouver group was part of the early antibody team associated with Amgen, said Grayson. “We have some veterans in San Diego on the discovery and development side, and then Vancouver is really a powerhouse for us on the technology side,” he said.

Samsara BioCapital Investments

70 Investments

Samsara BioCapital has made 70 investments. Their latest investment was in Tentarix Biotherapeutics as part of their Series A on October 10, 2021.

CBI Logo

Samsara BioCapital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/14/2021

Series A

Tentarix Biotherapeutics

$50M

Yes

8

10/5/2021

Series B

Exo Therapeutics

$78M

Yes

5

9/9/2021

Series B

Obsidian Therapeutics

$115M

Yes

4

9/8/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/8/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/14/2021

10/5/2021

9/9/2021

9/8/2021

9/8/2021

Round

Series A

Series B

Series B

Series B

Series A

Company

Tentarix Biotherapeutics

Exo Therapeutics

Obsidian Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$50M

$78M

$115M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

5

4

10

10

Samsara BioCapital Portfolio Exits

17 Portfolio Exits

Samsara BioCapital has 17 portfolio exits. Their latest portfolio exit was Graphite Bio on June 25, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/25/2021

IPO

$991

1

6/25/2021

IPO

$991

1

6/11/2021

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

6/25/2021

6/25/2021

6/11/2021

00/00/0000

00/00/0000

Exit

IPO

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Samsara BioCapital Fund History

2 Fund Histories

Samsara BioCapital has 2 funds, including Samsara BioCapital.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2020

Samsara BioCapital

5

3/1/2017

SMM SPV I

Subscribe to see more

$99M

10

Closing Date

12/31/2020

3/1/2017

Fund

Samsara BioCapital

SMM SPV I

Fund Type

Subscribe to see more

Status

Amount

$99M

Sources

5

10

Samsara BioCapital Team

3 Team Members

Samsara BioCapital has 3 team members, including current Chief Financial Officer, Richard Van Doren.

Name

Work History

Title

Status

Richard Van Doren

Marcato Capital Management, Cannell Capital, and EXP Systems

Chief Financial Officer

Current

Srini Akkaraju

Founding Partner

Current

Francis Ho

Investment Partner

Current

Name

Richard Van Doren

Srini Akkaraju

Francis Ho

Work History

Marcato Capital Management, Cannell Capital, and EXP Systems

Title

Chief Financial Officer

Founding Partner

Investment Partner

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.